Stockreport

Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid ...

ADURO BIOTECH  (ADRO) 
Last aduro biotech earnings: 3/9 04:15 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.aduro.com
PDF BERKELEY, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targ [Read more]